Manchester, UK-based Concept Life Sciences, an integrated drug discovery, development and analytical services company, has acquired Scottish contract research organisation Aquila BioMedical.
Aquila, a University of Edinburgh spin out, has expertise in preclinical contract research on therapeutics for oncology, biomarker discovery, and target expression, with services covering a wide range of in vitro and in vivo proof-of-concept studies.
According to Concept, the acquisition is “a pivotal addition” to its own services supporting the drug discovery and development process.
“The company’s offering in translational biology adds significant value to our current discovery services, and broadens the wider group’s therapy offering,” noted Concept’s executive chairman Michael Fort.
Financial terms of the deal were not disclosed.
By Selina McKee
Source: Pharma Times
CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.
DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.
Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.